Differences in Health Care Expenditures by Cancer Patients During Their Last Year of Life: A Registry-Based Study.

IF 2.8 4区 医学 Q2 ONCOLOGY Current oncology Pub Date : 2024-10-16 DOI:10.3390/curroncol31100462
Peter Strang, Max Petzold, Linda Björkhem-Bergman, Torbjörn Schultz
{"title":"Differences in Health Care Expenditures by Cancer Patients During Their Last Year of Life: A Registry-Based Study.","authors":"Peter Strang, Max Petzold, Linda Björkhem-Bergman, Torbjörn Schultz","doi":"10.3390/curroncol31100462","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>During the last year of life, persons with cancer should probably have similar care needs and costs, but studies suggest otherwise.</p><p><strong>Methods: </strong>A study of direct medical costs (excluding costs for expensive prescription drugs) was performed based on registry data in Stockholm County, which covers 2.4 million inhabitants, for all deceased persons with cancer during 2015-2021. The data were mainly analyzed with the aid of multiple regression models, including Generalized Linear Models (GLMs).</p><p><strong>Results: </strong>In a population of 20,431 deceased persons with cancer, the costs increased month by month (<i>p</i> < 0.0001). Higher costs were mainly associated with lower age (<i>p</i> < 0.0001), higher risk of frailty, as measured by the Hospital Frailty Risk Scale (<i>p</i> < 0.0001), and having a hematological malignancy. In a separate model, where those 5% with the highest costs were identified, these variables were strengthened. Sex and socio-economic groups on an area level had little or no significance. Systemic cancer treatments during the last month of life and acute hospitals as place of death had only a moderate impact on costs in adjusted models.</p><p><strong>Conclusions: </strong>Higher costs are mainly related to lower age, higher frailty risk and having a hematological malignancy, and the effects are both statistically and clinically significant despite the fact that expensive drugs were not included. On the other hand, the costs were mainly comparable in regard to sex or socio-economic factors, indicating equal care.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 10","pages":"6205-6217"},"PeriodicalIF":2.8000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11505941/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol31100462","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: During the last year of life, persons with cancer should probably have similar care needs and costs, but studies suggest otherwise.

Methods: A study of direct medical costs (excluding costs for expensive prescription drugs) was performed based on registry data in Stockholm County, which covers 2.4 million inhabitants, for all deceased persons with cancer during 2015-2021. The data were mainly analyzed with the aid of multiple regression models, including Generalized Linear Models (GLMs).

Results: In a population of 20,431 deceased persons with cancer, the costs increased month by month (p < 0.0001). Higher costs were mainly associated with lower age (p < 0.0001), higher risk of frailty, as measured by the Hospital Frailty Risk Scale (p < 0.0001), and having a hematological malignancy. In a separate model, where those 5% with the highest costs were identified, these variables were strengthened. Sex and socio-economic groups on an area level had little or no significance. Systemic cancer treatments during the last month of life and acute hospitals as place of death had only a moderate impact on costs in adjusted models.

Conclusions: Higher costs are mainly related to lower age, higher frailty risk and having a hematological malignancy, and the effects are both statistically and clinically significant despite the fact that expensive drugs were not included. On the other hand, the costs were mainly comparable in regard to sex or socio-economic factors, indicating equal care.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
癌症患者在生命最后一年的医疗支出差异:基于登记册的研究。
背景:在癌症患者生命的最后一年里,他们的护理需求和成本应该是相似的:在生命的最后一年,癌症患者应该有相似的护理需求和费用,但研究表明并非如此:根据斯德哥尔摩县的登记数据,对 2015-2021 年间所有已故癌症患者的直接医疗费用(不包括昂贵处方药的费用)进行了研究。数据主要借助多元回归模型(包括广义线性模型)进行分析:在 20431 名癌症患者中,费用逐月增加(p < 0.0001)。较高的费用主要与较低的年龄(p < 0.0001)、较高的虚弱风险(以医院虚弱风险量表衡量)(p < 0.0001)以及血液恶性肿瘤有关。在一个单独的模型中,确定了费用最高的 5%,这些变量得到了加强。在地区层面上,性别和社会经济群体的影响很小或没有影响。在调整后的模型中,生命最后一个月的系统性癌症治疗和急症医院作为死亡地点对费用的影响不大:较高的成本主要与较低的年龄、较高的虚弱风险和患有血液恶性肿瘤有关,尽管昂贵的药物未被包括在内,但其影响在统计和临床上都是显著的。另一方面,费用主要与性别或社会经济因素有关,这表明护理是平等的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current oncology
Current oncology ONCOLOGY-
CiteScore
3.30
自引率
7.70%
发文量
664
审稿时长
1 months
期刊介绍: Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.
期刊最新文献
Sex-Related Differences in Immunotherapy Outcomes of Patients with Advanced Non-Small Cell Lung Cancer. Sociocultural and Clinical Determinants of Sexual Dysfunction in Perimenopausal Women with and Without Breast Cancer. Electrochemotherapy in the Locoregional Treatment of Metastatic Colorectal Liver Metastases: A Systematic Review. Exploiting Integrin-αVβ3 to Enhance Radiotherapy Efficacy in Medulloblastoma via Ferroptosis. Fostering the Conversation About Complementary Medicine: Acceptability and Usefulness of Two Communication-Supporting Tools for Patients with Cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1